Brands
Mukta Arts posts strong revenue and profit rise
MUMBAI: Mukta Arts Limited, the film production house helmed by veteran director Subhash Ghai, turned in a performance worthy of a standing ovation for the quarter ended 30 September 2025. The company’s standalone net profit soared to Rs 1.74 crore, more than double last year’s Rs 76.7 lakh, while revenue from operations rose 46 per cent year-on-year to Rs 4.85 crore.
Other income also gave the script a happy twist, contributing Rs 7.97 crore and taking total revenue to Rs 12.02 crore against Rs 10.34 crore in the same period last year.
Expenses rose modestly to Rs 10.22 crore from Rs 8.83 crore, largely due to higher employee costs and depreciation. Yet the bottom line stayed in the black, helped by better cost control and improved returns from its film, distribution and education segments.
On a consolidated basis, however, the group posted a loss of Rs 3.56 crore, weighed down by weaker performance at its subsidiaries including Whistling Woods International and Mukta A2 Cinemas.
The auditors flagged the long-running land lease dispute concerning Whistling Woods International, noting that the matter remains sub judice before the Bombay High Court, and said its outcome could affect valuations.
Despite these ongoing plotlines, Mukta’s financial direction seems to have regained its narrative focus. With the lights back on in cinemas and fresh productions on the floor, the studio appears ready for its next act.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
